Clostridioides difficile infection (CDI) is a major public health concern for pediatric and adult patients. The management of pediatric CDI poses a challenge to healthcare providers due to lack of strong randomized controlled trials to guide pharmacological management. Additionally, recent updates to CDI guidelines recommend oral vancomycin over metronidazole for the management of CDI in adults, leaving questions regarding how to best manage pediatric patients. This continuing education pharmacotherapy review describes available evidence for the safety and efficacy of medications used in the treatment and management of pediatric CDI and aims to clarify discrepancies between pediatric and adult recommendations.

艰难梭菌感染 (CDI) 是儿科和成人患者的主要公共卫生问题。由于缺乏强有力的随机对照试验来指导药物管理，儿科 CDI 的管理对医疗保健提供者构成了挑战。此外，最近对 CDI 指南的更新建议口服万古霉素优于甲硝唑来治疗成人 CDI，留下关于如何最好地管理儿科患者的问题。该继续教育药物治疗综述描述了用于治疗和管理儿科 CDI 的药物的安全性和有效性的现有证据，旨在澄清儿科和成人建议之间的差异。